Cargando…

Chromothripsis and progression-free survival in metastatic colorectal cancer

Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Skuja, Elina, Kalniete, Dagnija, Nakazawa-Miklasevica, Miki, Daneberga, Zanda, Abolins, Arnis, Purkalne, Gunta, Miklasevics, Edvins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351707/
https://www.ncbi.nlm.nih.gov/pubmed/28357089
http://dx.doi.org/10.3892/mco.2017.1123
_version_ 1782514819245539328
author Skuja, Elina
Kalniete, Dagnija
Nakazawa-Miklasevica, Miki
Daneberga, Zanda
Abolins, Arnis
Purkalne, Gunta
Miklasevics, Edvins
author_facet Skuja, Elina
Kalniete, Dagnija
Nakazawa-Miklasevica, Miki
Daneberga, Zanda
Abolins, Arnis
Purkalne, Gunta
Miklasevics, Edvins
author_sort Skuja, Elina
collection PubMed
description Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromothripsis and total breakpoint count (breakpoint instability index) on progression-free survival (PFS). A total of 19 patients with metastatic CRC (mCRC) receiving FOLFOX first-line palliative chemotherapy between August, 2011 and October, 2012 were selected for this study. The results indicated that the highest breakpoint count was observed in chromosomes 1, 2 and 6. Chromothripsis was detected in 52.6% of the study patients. Furthermore, chromothripsis was associated with an increased median PFS (mPFS; 14 vs. 8 months, respectively; P=0.03), but an association with overall survival was not identified. The present study demonstrated that chromothripsis affected CRC patient survival, suggesting a role for this event as a prognostic and predictive marker in mCRC treatment.
format Online
Article
Text
id pubmed-5351707
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-53517072017-03-29 Chromothripsis and progression-free survival in metastatic colorectal cancer Skuja, Elina Kalniete, Dagnija Nakazawa-Miklasevica, Miki Daneberga, Zanda Abolins, Arnis Purkalne, Gunta Miklasevics, Edvins Mol Clin Oncol Articles Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromothripsis and total breakpoint count (breakpoint instability index) on progression-free survival (PFS). A total of 19 patients with metastatic CRC (mCRC) receiving FOLFOX first-line palliative chemotherapy between August, 2011 and October, 2012 were selected for this study. The results indicated that the highest breakpoint count was observed in chromosomes 1, 2 and 6. Chromothripsis was detected in 52.6% of the study patients. Furthermore, chromothripsis was associated with an increased median PFS (mPFS; 14 vs. 8 months, respectively; P=0.03), but an association with overall survival was not identified. The present study demonstrated that chromothripsis affected CRC patient survival, suggesting a role for this event as a prognostic and predictive marker in mCRC treatment. D.A. Spandidos 2017-02 2017-01-02 /pmc/articles/PMC5351707/ /pubmed/28357089 http://dx.doi.org/10.3892/mco.2017.1123 Text en Copyright: © Skuja et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Skuja, Elina
Kalniete, Dagnija
Nakazawa-Miklasevica, Miki
Daneberga, Zanda
Abolins, Arnis
Purkalne, Gunta
Miklasevics, Edvins
Chromothripsis and progression-free survival in metastatic colorectal cancer
title Chromothripsis and progression-free survival in metastatic colorectal cancer
title_full Chromothripsis and progression-free survival in metastatic colorectal cancer
title_fullStr Chromothripsis and progression-free survival in metastatic colorectal cancer
title_full_unstemmed Chromothripsis and progression-free survival in metastatic colorectal cancer
title_short Chromothripsis and progression-free survival in metastatic colorectal cancer
title_sort chromothripsis and progression-free survival in metastatic colorectal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351707/
https://www.ncbi.nlm.nih.gov/pubmed/28357089
http://dx.doi.org/10.3892/mco.2017.1123
work_keys_str_mv AT skujaelina chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer
AT kalnietedagnija chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer
AT nakazawamiklasevicamiki chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer
AT danebergazanda chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer
AT abolinsarnis chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer
AT purkalnegunta chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer
AT miklasevicsedvins chromothripsisandprogressionfreesurvivalinmetastaticcolorectalcancer